Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine versus duloxetine with dicyclomine in constipation-predominant irritable bowel syndrome
IRCT20171115037478N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluoxetine, duloxetine and dicyclomine in irritable bowel syndrome (IBS) (3 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Constipation, Abdominal pain and 2 more. Started Jun 2017; status: completed.
02
Drugs
fluoxetineduloxetinedicyclomine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20171115037478N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171115037478N1.